N
IMRX icon

Natixis’s Immuneering IMRX Stock Holding History

Natixis’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2K Buy
+380
New +$1.95K ﹤0.01% 1055

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Natixis's IMRX Position: Q1 2026 in Review

Natixis opened a new position in Immuneering (IMRX) in Q1 2026: 380 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #1055 among its holdings.

95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Natixis held 380 shares of Immuneering worth $2K as of Q1 2026.
  • Immuneering was a new Natixis position in Q1 2026.
  • Immuneering made up ﹤0.01% of Natixis's portfolio in Q1 2026, its #1055 holding.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.